Inventor · disambiguated record
Andrew Geall
Also filed as: GEALL ANDREW · GEALL ANDREW J · GEALL ANDREW JOHN
101 granted patents·43 pending applications·1,618 citations·filing 2003–2025
99Inventor score
Files withGLAXOSMITHKLINE BIOLOGICALS SA56AVIDITY BIOSCIENCES INC36GEALL ANDREW13VICAL INC11NOVARTIS AG9
Top patents by PatentIndex Score
144 records- 0199US11883534B2Immunisation with lipid formulations with RNA encoding immunogensGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2023·Granted Jan 30, 2024·5 cites·30 claims
- 0299US11786467B2Lipid formulations with immunogensGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2021·Granted Oct 17, 2023·11 cites·32 claims
- 0399US11766401B2Methods of administering lipid formulations with immunogensGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2021·Granted Sep 26, 2023·11 cites·29 claims
- 0499US11707482B2Delivery of RNA to trigger multiple immune pathwaysGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Jul 25, 2023·7 cites·30 claims
- 0599US11690862B1Delivery of RNA to trigger multiple immune pathwaysGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Jul 4, 2023·7 cites·46 claims
- 0699US11666534B2Methods of administering lipid formulations with viral immunogensGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2021·Granted Jun 6, 2023·14 cites·37 claims
- 0799US11638693B2Vaccine for eliciting immune response comprising RNA encoding an immunogen and lipid formulations comprising mole percentage of lipidsGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted May 2, 2023·15 cites·30 claims
- 0899US11638694B2Vaccine for eliciting immune response comprising lipid formulations and RNA encoding multiple immunogensGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted May 2, 2023·14 cites·30 claims
- 0999US11596645B2Delivery of RNA to trigger multiple immune pathwaysGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2021·Granted Mar 7, 2023·7 cites·103 claims
- 1099US11324770B2Delivery of RNA to trigger multiple immune pathwaysGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2020·Granted May 10, 2022·38 cites·114 claims
- 1199US11291682B2Delivery of RNA to trigger multiple immune pathwaysGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2019·Granted Apr 5, 2022·48 cites·102 claims
- 1299US10532067B2Delivery of RNA to trigger multiple immune pathwaysGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2017·Granted Jan 14, 2020·66 cites·6 claims
- 1398US12064483B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2022·Granted Aug 20, 2024·19 cites·24 claims
- 1498US11857681B2Lipid formulations with RNA encoding immunogensGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2023·Granted Jan 2, 2024·3 cites·30 claims
- 1598US11850305B2Method of making lipid formulations with RNA encoding immunogensGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2023·Granted Dec 26, 2023·4 cites·30 claims
- 1698US11717529B2Delivery of RNA to trigger multiple immune pathwaysGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Aug 8, 2023·5 cites·46 claims
- 1798US11696923B2Delivery of RNA to trigger multiple immune pathwaysGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Jul 11, 2023·4 cites·46 claims
- 1898US11690861B2Delivery of RNA to trigger multiple immune pathwaysGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Jul 4, 2023·5 cites·30 claims
- 1998US11690863B2Delivery of RNA to trigger multiple immune pathwaysGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Jul 4, 2023·4 cites·46 claims
- 2098US11690865B2Delivery of RNA to trigger multiple immune pathwaysGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Jul 4, 2023·4 cites·46 claims
- 2198US11400163B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2021·Granted Aug 2, 2022·26 cites·22 claims
- 2298US11311627B1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2021·Granted Apr 26, 2022·28 cites·24 claims
- 2398US11253607B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2020·Granted Feb 22, 2022·7 cites·23 claims
- 2498US11246941B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 15, 2022·7 cites·23 claims
- 2598US11179472B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2018·Granted Nov 23, 2021·35 cites·25 claims
- 2698US11135287B2Method for preparing composition comprising a cationic oil-in-water emulsionGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2019·Granted Oct 5, 2021·26 cites·20 claims
- 2798US11058762B2Immunogenic compositions and uses thereofGEALL ANDREW·Filed 2012·Granted Jul 13, 2021·43 cites·21 claims
- 2898US11026964B2Delivery of RNA to different cell typesGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2017·Granted Jun 8, 2021·46 cites·18 claims
- 2998US10994020B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2018·Granted May 4, 2021·32 cites·24 claims
- 3098US10906867B2Lipids and lipid compositions for the delivery of active agentsNOVARTIS AG·Filed 2018·Granted Feb 2, 2021·39 cites·20 claims
- 3198US10881743B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2019·Granted Jan 5, 2021·55 cites·16 claims
- 3298US10787519B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Sep 29, 2020·19 cites·17 claims
- 3398US10550188B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Feb 4, 2020·80 cites·13 claims
- 3498US10487332B2Immunisation of large mammals with low doses of RNAGEALL ANDREW·Filed 2011·Granted Nov 26, 2019·65 cites·20 claims
- 3598US10238733B2Cationic oil-in-water emulsionsGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2016·Granted Mar 26, 2019·37 cites·32 claims
- 3698US9801897B2Delivery of RNA to trigger multiple immune pathwaysGEALL ANDREW·Filed 2011·Granted Oct 31, 2017·73 cites·14 claims
- 3797US11905514B2Immunisation of large mammals with low doses of RNAGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Feb 20, 2024·1 cites·30 claims
- 3897US11891608B2Immunization of large mammals with low doses of RNAGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Feb 6, 2024·1 cites·30 claims
- 3997US11851660B2Immunisation of large mammals with low doses of RNAGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Dec 26, 2023·1 cites·30 claims
- 4097US11845925B2Immunisation of large mammals with low doses of RNAGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Dec 19, 2023·1 cites·30 claims
- 4197US11839686B2Lipid formulations with viral immunogensGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2021·Granted Dec 12, 2023·2 cites·33 claims
- 4297US11773395B1Immunization of large mammals with low doses of RNAGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Oct 3, 2023·1 cites·30 claims
- 4397US11739334B2Immunisation of large mammals with low doses of RNAGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Aug 29, 2023·1 cites·30 claims
- 4497US11690864B2Delivery of RNA to trigger multiple immune pathwaysGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Jul 4, 2023·2 cites·30 claims
- 4597US11655475B2Immunisation of large mammals with low doses of RNAGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2019·Granted May 23, 2023·6 cites·68 claims
- 4697US11576980B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 14, 2023·6 cites·23 claims
- 4797US11497814B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Nov 15, 2022·3 cites·30 claims
- 4897US10487149B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Nov 26, 2019·21 cites·18 claims
- 4997US9770463B2Delivery of RNA to different cell typesGEALL ANDREW·Filed 2011·Granted Sep 26, 2017·73 cites·18 claims
- 5097US9295646B2Cationic oil-in-water emulsionsBRITO LUIS·Filed 2011·Granted Mar 29, 2016·48 cites·32 claims
Showing the top 50 of 144 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Andrew Geall files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →